14,797
edits
Helminthic therapy and COVID-19: Difference between revisions
Helminthic therapy and COVID-19 (view source)
Revision as of 04:17, 18 February 2023
, 18 February 2023→The emerging science: Added citation.
m (→The emerging science: Added full text and PDF links.) |
m (→The emerging science: Added citation.) |
||
| Line 16: | Line 16: | ||
== The emerging science == | == The emerging science == | ||
* 2023 Feb 9 [https://pubmed.ncbi.nlm.nih.gov/36785786/ COVID-19 morbidity in lower versus higher income populations underscores the need to restore lost biodiversity of eukaryotic symbionts] | [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908430/pdf/main.pdf PDF] | |||
:{{Quote|indent}}… it is now apparent that 'biome reconstitution', defined as the artificial re-introduction of benign, symbiotic helminths or protists into the ecosystem of the human body, is important not only for alleviation of chronic immune disease, but likely also for pandemic preparedness.{{Quote|/indent}} | |||
* 2022 Nov 10 [https://www.biorxiv.org/content/10.1101/2022.11.09.515832v1 Helminth exposure protects against murine SARS-CoV-2 infection through macrophage dependent T cell activation] -- [https://www.biorxiv.org/content/10.1101/2022.11.09.515832v1.full Full text] | [https://www.biorxiv.org/content/10.1101/2022.11.09.515832v1.full.pdf PDF] | * 2022 Nov 10 [https://www.biorxiv.org/content/10.1101/2022.11.09.515832v1 Helminth exposure protects against murine SARS-CoV-2 infection through macrophage dependent T cell activation] -- [https://www.biorxiv.org/content/10.1101/2022.11.09.515832v1.full Full text] | [https://www.biorxiv.org/content/10.1101/2022.11.09.515832v1.full.pdf PDF] | ||